Search reports, ask a question, or jump to a page.
The problem
Intervention: COVID-19 vaccination (BNT162b2, mRNA-1273, or ChAdOX1) in children and adolescents aged 5-17 years
Who it was tested with: 5.1 million children in England aged 5-17 years.
Experience from people who deliver programmes: stories, case studies and lessons learned. Valuable for understanding how and why, and for spotting what to test next, but not a measure of effect.
"A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection." This design allows comparison of risk periods within individuals over time, providing evidence on vaccination safety in a large population.
Self-controlled case-series design may not fully capture all potential confounders; confidence intervals for some outcomes cross zero; study measures hospitalizations rather than all adverse events; follow-up period limited to 42 days post-vaccination
Across countries and designs
1 study · 1 country
